CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

CytomX Therapeutics Price Performance

Shares of CTMX opened at $1.02 on Monday. The business’s fifty day moving average is $1.07 and its 200 day moving average is $1.29. CytomX Therapeutics has a 12-month low of $0.83 and a 12-month high of $5.85. The stock has a market cap of $79.83 million, a P/E ratio of 6.00 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period last year, the firm earned $0.04 earnings per share. On average, analysts expect that CytomX Therapeutics will post -0.05 EPS for the current year.

Institutional Trading of CytomX Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CTMX. Jacobs Levy Equity Management Inc. grew its position in CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of CytomX Therapeutics in the 1st quarter worth approximately $57,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares in the last quarter. US Bancorp DE purchased a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $40,000. Finally, Geode Capital Management LLC increased its position in shares of CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.